The GLOW trial in chronic lymphocytic leukaemia
- 29 January 2024
- journal article
- letter
- Published by Elsevier in The Lancet Oncology
- Vol. 25 (2) , e55
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialThe Lancet Oncology, 2023
- Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesNEJM Evidence, 2022
- First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trialHaematologica, 2022
- COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL studyLeukemia, 2021
- Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialThe Lancet Oncology, 2020